{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:33:06Z","timestamp":1772461986376,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency, characterized by inadequate antibody responses and recurrent bacterial infections. Paradoxically, a majority of CVID patients have non-infectious inflammatory and autoimmune complications, associated with systemic immune activation. Our aim was to explore if HDL, known to have anti-inflammatory properties, had impaired function in CVID patients and thereby contributed to their inflammatory phenotype. We found reduced HDL cholesterol levels in plasma of CVID patients compared to healthy controls, particularly in patients with inflammatory and autoimmune complications, correlating negatively with inflammatory markers CRP and sCD25. Reverse cholesterol transport capacity testing showed reduced serum acceptance capacity for cholesterol in CVID patients with inflammatory and autoimmune complications. They also had reduced cholesterol efflux capacity from macrophages to serum and decreased expression of ATP-binding cassette transporter ABCA1. Human HDL suppressed TLR2-induced TNF release less in blood mononuclear cells from CVID patients, associated with decreased expression of transcriptional factor ATF3. Our data suggest a link between impaired HDL function and systemic inflammation in CVID patients, particularly in those with autoimmune and inflammatory complications. This identifies HDL as a novel therapeutic target in CVID as well as other more common conditions characterized by sterile inflammation or autoimmunity.<\/jats:p>","DOI":"10.1038\/s41598-019-45861-1","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T10:03:09Z","timestamp":1561975389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency"],"prefix":"10.1038","volume":"9","author":[{"given":"Magnhild E.","family":"Macpherson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom E.","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf K.","family":"Berge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azita","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Otterdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang Y.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten B.","family":"Holven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00f8rre","family":"Fevang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silje F.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"key":"45861_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01131.x","volume":"120","author":"L Hammarstr\u00f6m","year":"2000","unstructured":"Hammarstr\u00f6m, L., Vorechovsky, I. & Webster, D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin. Exp. Immunol. 120, 225\u2013231 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"45861_CR2","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1038\/cti.2015.41","volume":"5","author":"AG Louis","year":"2016","unstructured":"Louis, A. G., Yel, L., Cao, J. N., Agrawal, S. & Gupta, S. Common variable immunodeficiency associated with microdeletion of chromosome 1q42. 1\u2010q42. 3 and inositol 1, 4, 5\u2010trisphosphate kinase B (ITPKB) deficiency. Clin. Transl. Immunol. 5, e59 (2016).","journal-title":"Clin. Transl. Immunol."},{"key":"45861_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/jmedgenet-2015-103690","volume":"53","author":"DJ Bogaert","year":"2016","unstructured":"Bogaert, D. J. et al. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J. Med. Genet. 53, 575\u2013590 (2016).","journal-title":"J. Med. Genet."},{"key":"45861_CR4","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2018.00636","volume":"9","author":"G de Valles-Ib\u00e1\u00f1ez","year":"2018","unstructured":"de Valles-Ib\u00e1\u00f1ez, G. et al. evaluating the genetics of common Variable immunodeficiency: Monogenetic Model and Beyond. Front. Immunol. 9, 636 (2018).","journal-title":"Front. Immunol."},{"key":"45861_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cei.12947","volume":"188","author":"AK Kienzler","year":"2017","unstructured":"Kienzler, A. K., Hargreaves, C. E. & Patel, S. Y. The role of genomics in common variable immunodeficiency disorders. Clin. Exp. Immunol. 188, 326\u2013332 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"45861_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10875-018-0574-z","volume":"39","author":"SF J\u00f8rgensen","year":"2019","unstructured":"J\u00f8rgensen, S. F., Fevang, B. & Aukrust, P. Autoimmunity and Inflammation in CVID: a Possible Crosstalk between Immune Activation, Gut Microbiota, and Epigenetic Modifications. J. Clin. Immunol. 39, 30\u201336 (2019).","journal-title":"J. Clin. Immunol."},{"key":"45861_CR7","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","volume":"119","author":"ES Resnick","year":"2012","unstructured":"Resnick, E. S., Moshier, E. L., Godbold, J. H. & Cunningham-Rundles, C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 119, 1650\u20131657 (2012).","journal-title":"Blood"},{"key":"45861_CR8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V87.2.674.bloodjournal872674","volume":"87","author":"P Aukrust","year":"1996","unstructured":"Aukrust, P. et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency -possible immunologic and clinical consequences. Blood 87, 674\u2013681 (1996).","journal-title":"Blood"},{"key":"45861_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2249.2006.03314.x","volume":"147","author":"B Fevang","year":"2007","unstructured":"Fevang, B. et al. Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin. Exp. Immunol. 147, 521\u2013525 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"45861_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10875-014-0099-z","volume":"34","author":"Z Hel","year":"2014","unstructured":"Hel, Z. et al. Altered serum cytokine signature in common variable immunodeficiency. J. Clin. Immunol. 34, 971\u2013978 (2014).","journal-title":"J. Clin. Immunol."},{"key":"45861_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2249.2012.04655.x","volume":"170","author":"J Litzman","year":"2012","unstructured":"Litzman, J. et al. Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD 14 and CD 25 but not endotoxaemia. Clin. Exp. Immunol. 170, 321\u2013332 (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"45861_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","volume":"125","author":"M Lucas","year":"2010","unstructured":"Lucas, M. et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy Clin. Immunol. 125, 1354\u20131360 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"45861_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12728","volume":"287","author":"C Cunningham\u2010Rundles","year":"2019","unstructured":"Cunningham\u2010Rundles, C. Common variable immune deficiency: Dissection of the variable. Immunol. Rev. 287, 145\u2013161 (2019).","journal-title":"Immunol. Rev."},{"key":"45861_CR14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1097\/01.CCM.0000171183.79525.6B","volume":"33","author":"J-Y Chien","year":"2005","unstructured":"Chien, J.-Y., Jerng, J.-S., Yu, C.-J. & Yang, P.-C. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit. Care Med. 33, 1688\u20131693 (2005).","journal-title":"Crit. Care Med."},{"key":"45861_CR15","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s10620-012-2127-2","volume":"57","author":"HR Williams","year":"2012","unstructured":"Williams, H. R. et al. Serum metabolic profiling in inflammatory bowel disease. Dig. Dis. Sci. 57, 2157\u20132165 (2012).","journal-title":"Dig. Dis. Sci."},{"key":"45861_CR16","doi-asserted-by":"crossref","unstructured":"McMahon, K. M. et al. Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer 166, 129\u2013150 (Springer, 2015).","DOI":"10.1007\/978-3-319-16555-4_6"},{"key":"45861_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/ni.2784","volume":"15","author":"D De Nardo","year":"2014","unstructured":"De Nardo, D. et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat. Immunol. 15, 152\u2013160 (2014).","journal-title":"Nat. Immunol."},{"key":"45861_CR18","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.cmet.2017.04.005","volume":"25","author":"M Westerterp","year":"2017","unstructured":"Westerterp, M. et al. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell metabolism 25, 1294\u20131304 (2017).","journal-title":"Cell metabolism"},{"key":"45861_CR19","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1194\/jlr.R036095","volume":"54","author":"A Kontush","year":"2013","unstructured":"Kontush, A., Lhomme, M. & Chapman, M. J. Unraveling the complexities of the HDL lipidome. J. Lipid Res. 54, 2950\u20132963 (2013).","journal-title":"J. Lipid Res."},{"key":"45861_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/CIRCRESAHA.115.306052","volume":"116","author":"JW Heinecke","year":"2015","unstructured":"Heinecke, J. W. Small HDL promotes cholesterol efflux by the ABCA1 pathway in macrophages: implications for therapies targeted to HDL. Circ. Res. 116, 1101\u20131103 (2015).","journal-title":"Circ. Res."},{"key":"45861_CR21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.116.305485","volume":"116","author":"X-M Du","year":"2015","unstructured":"Du, X.-M. et al. HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol Export. Circ. Res. 116, 1133\u20131142 (2015).","journal-title":"Circ. Res."},{"key":"45861_CR22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-2275(20)32028-9","volume":"41","author":"PG Frank","year":"2000","unstructured":"Frank, P. G. & Marcel, Y. L. Apolipoprotein AI: structure\u2013function relationships. J. Lipid Res. 41, 853\u2013872 (2000).","journal-title":"J. Lipid Res."},{"key":"45861_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000435818","volume":"66","author":"DG Vieira","year":"2015","unstructured":"Vieira, D. G. et al. Higher Cardiovascular Risk in Common Variable Immunodeficiency and X-Linked Agammaglobulinaemia Patients. Ann. Nutr. Metab. 66, 237\u2013241 (2015).","journal-title":"Ann. Nutr. Metab."},{"key":"45861_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jacl.2010.08.021","volume":"4","author":"RSRS Biyyani","year":"2010","unstructured":"Biyyani, R. S. R. S., Putka, B. S. & Mullen, K. D. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J. Clin. Lipidol. 4, 478\u2013482 (2010).","journal-title":"J. Clin. Lipidol."},{"key":"45861_CR25","doi-asserted-by":"publisher","first-page":"e001588","DOI":"10.1161\/JAHA.114.001588","volume":"4","author":"KP Liao","year":"2015","unstructured":"Liao, K. P. et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. Journal of the American Heart Association 4, e001588 (2015).","journal-title":"Journal of the American Heart Association"},{"key":"45861_CR26","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/art.11264","volume":"48","author":"E Svenungsson","year":"2003","unstructured":"Svenungsson, E. et al. Elevated triglycerides and low levels of high\u2010density lipoprotein as markers of disease activity in association with up\u2010regulation of the tumor necrosis factor \u03b1\/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 48, 2533\u20132540 (2003).","journal-title":"Arthritis Rheum."},{"key":"45861_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/rheumatology\/kei190","volume":"45","author":"B Lodde","year":"2006","unstructured":"Lodde, B. et al. Serum lipid levels in Sjogren\u2019s syndrome. Rheumatology 45, 481\u2013484 (2006).","journal-title":"Rheumatology"},{"key":"45861_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.117.032636","volume":"138","author":"M Westerterp","year":"2018","unstructured":"Westerterp, M. et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis and Atherogenesis. Circulation 138, 898\u2013912 (2018).","journal-title":"Circulation"},{"key":"45861_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.mehy.2015.07.002","volume":"85","author":"R Ucar","year":"2015","unstructured":"Ucar, R., Arslan, S., Turkmen, K. & Caliskaner, A. Z. Accelerated atherosclerosis in patients with common variable immunodeficiency: Is it overlooked or absent? Med. Hypotheses 85, 485\u2013487 (2015).","journal-title":"Med. Hypotheses"},{"key":"45861_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","volume":"134","author":"B Gathmann","year":"2014","unstructured":"Gathmann, B. et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J. Allergy Clin. Immunol. 134, 116\u2013126 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"45861_CR31","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/ajg.2016.329","volume":"111","author":"SF J\u00f8rgensen","year":"2016","unstructured":"J\u00f8rgensen, S. F. et al. A cross-sectional study of the prevalence of gastrointestinal symptoms and pathology in patients with common variable immunodeficiency. The American Journal of Gastroenterology 111, 1467\u20131475 (2016).","journal-title":"The American Journal of Gastroenterology"},{"key":"45861_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2018.09.008","volume":"197","author":"N Shulzhenko","year":"2018","unstructured":"Shulzhenko, N. et al. CVID enteropathy is characterized by exceeding low mucosal IgA levels and interferon-driven inflammation possibly related to the presence of a pathobiont. Clin. Immunol. 197, 139\u2013153 (2018).","journal-title":"Clin. Immunol."},{"key":"45861_CR33","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/CIRCRESAHA.115.306807","volume":"117","author":"J Fu","year":"2015","unstructured":"Fu, J. et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ. Res. 117, 817\u2013824 (2015).","journal-title":"Circ. Res."},{"key":"45861_CR34","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/mi.2016.18","volume":"9","author":"S J\u00f8rgensen","year":"2016","unstructured":"J\u00f8rgensen, S. et al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol. 9, 1455\u20131465 (2016).","journal-title":"Mucosal Immunol."},{"key":"45861_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.atherosclerosis.2012.02.032","volume":"222","author":"M De La Llera Moya","year":"2012","unstructured":"De La Llera Moya, M. et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 222, 390\u2013394 (2012).","journal-title":"Atherosclerosis"},{"key":"45861_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/ATVBAHA.109.187518","volume":"30","author":"M Navab","year":"2010","unstructured":"Navab, M. et al. Structure and function of HDL mimetics. Art. Thromb. Vasc. Biol. 30, 164\u2013168 (2010).","journal-title":"Structure and function of HDL mimetics. Art. Thromb. Vasc. Biol."},{"key":"45861_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","volume":"31","author":"MJ Chapman","year":"2010","unstructured":"Chapman, M. J., Le Goff, W., Guerin, M. & Kontush, A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31, 149\u2013164 (2010).","journal-title":"Eur. Heart J."},{"key":"45861_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35367-7","volume":"9","author":"SF Jorgensen","year":"2019","unstructured":"Jorgensen, S. F. et al. Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Sci. Rep. 9, 167 (2019).","journal-title":"Sci. Rep."},{"key":"45861_CR39","first-page":"192","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen, P., Kangas, A. J., W\u00fcrtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circulation: Cardiovasc. Genetics 8, 192\u2013206 (2015).","journal-title":"Circulation: Cardiovasc. Genetics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45861-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:57:30Z","timestamp":1671274650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45861-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45861"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45861-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.B.H. has received research grants and\/or personal fees from Tine DA, Mills DA, Olympic Seafood, Amgen, Kaneka, Sanofi, and Pronova, none of which are related to the content of this manuscript. All remaining authors declare no potential financial nor non-financial conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9427"}}